Acrux (ASX:ACR) and its partner, TruPharma, rolled out a 90-gram pack of Dapsone 5% Gel in the US, according to a Thursday filing with the Australian bourse.
Dapsone 5% Gel is a topical prescription medicine to treat acne vulgaris, per the filing.
Annual market sales for the product reached more than $15.8 million in the 12 months ended August 2024.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。